In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Norgine gets rights to Tranzyme's GI candidate ulimorelin; deal terminated

Executive Summary

Drug discovery firm Tranzyme Pharma Inc. has licensed specialty pharmaco Norgine BV exclusive rights to develop and commercialize injectable formulations of its ghrelin receptor agonist ulimorelin (TZP101) in Europe, Australia, New Zealand, the Middle East, South Africa, and North Africa.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register